Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733169 | 0.92 | CCR4 (0.71) | CCR4 | |
| SCHEMBL1733258 | 0.87 | CCR4 (0.66) | CCR4 | |
| SCHEMBL2421697 | 0.87 | CCR4 (0.53) | CCR4 | |
| SCHEMBL1732934 | 0.84 | CCR4 (0.69) | CCR4 | |
| SCHEMBL1732797 | 0.84 | CCR4 (0.87) | CCR4 | |
| SCHEMBL1732791 | 0.81 | CCR4 (0.74) | CCR4 | |
| SCHEMBL1731964 | 0.80 | CCR4 (1.00) | CCR4 | |
| SCHEMBL2427201 | 0.80 | CCR4 (0.58) | CCR4 | |
| Hydrochloric Acid SCHEMBL1733017 | 0.80 | CCR4 (0.72) | CCR4 | |
| SCHEMBL6182891 | 0.80 | KDM4E (0.48) | CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467976-B1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2011-11-23 | — | — | EP | claimed |
| WO-2011081310-A3 | PEPTIDE MARKER FOR CANCER DIAGNOSIS, AND CANCER DIAGNOSIS METHOD USING SAME | 한국기초과학지원연구원 (KR) | 2011-10-27 | — | — | WO | claimed |
| US-20100081670-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | BAXTER ANDREW | 2010-04-01 | — | — | US | claimed |
| US-20060025423-A1 | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | claimed |
| EP-1467976-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2004-10-20 | — | — | EP | claimed |
| WO-2003059893-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | WO | claimed |
| EP-1467976-B1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2011-11-23 | — | — | EP | disclosed |
| WO-2011081310-A3 | PEPTIDE MARKER FOR CANCER DIAGNOSIS, AND CANCER DIAGNOSIS METHOD USING SAME | 한국기초과학지원연구원 (KR) | 2011-10-27 | — | — | WO | disclosed |
| US-20100081670-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | BAXTER ANDREW | 2010-04-01 | — | — | US | disclosed |
| US-20100081670-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | BAXTER ANDREW | 2010-04-01 | — | — | US | disclosed |
| US-20100081670-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | BAXTER ANDREW | 2010-04-01 | — | — | US | disclosed |
| US-7662825-B2 | 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| US-7662825-B2 | 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| US-7662825-B2 | 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| US-20060025423-A1 | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025423-A1 | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases | CCL11, CCL2, CCR2 | CCR4 20/4885 |
| US-20100081670-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | CCL11, CCL2, CCR2 | CCR4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.